Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ERYTHROMYCIN BASE

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (J01FA) — coverage varies; not interchangeable

  • Azithromycin (Zithromax): general benefit, Limited Use 549, Not a benefit
  • Clarithromycin (Biaxin XL): general benefit, Not a benefit
  • Erythromycin estolate (Ilosone): general benefit, Not a benefit
  • Erythromycin ethylsuccinate (Ees-200): general benefit, Not a benefit

Erythro-Base · DIN 00682020 · 250mg · tablet

General benefitDormant since 2022-02-19 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Erythro-Base · DIN 00682020 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.7460 Health Canada: Dormant since 2022-02-19 · brand ERYTHRO-BASE · ATC J01FA01 ERYTHROMYCIN · form Tablet · route Oral · ingredients ERYTHROMYCIN 250 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Erythro-Base: Formulary list price $0.1865/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1865 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6687 · Verify on the e-Formulary ↗ (DIN 00682020)

Source record
DIN 00682020: Erythro-Base Raw flags: sec3=Y Item: 081212001; group id 22; item number 0037; lccId None; manufacturer id AAP Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.1865; ministry $0.1865 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00682020 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6687
Interchangeable products
Erythromid · DIN 00244635 · not recorded
Shortage status: discontinued (2022-04-01, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00682020
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2022-02-19 — choose a marketed DIN from the same-category list.

Erythromid · DIN 00244635 · 250mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-06-06 — choose a marketed DIN from the same-category list.Discontinued 2008-06-06 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-06-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-06-06 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Erythromid · DIN 00244635 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Daily cost (source): $0.7460 Health Canada: Cancelled post market since 2008-06-06 · brand ERYTHROMID TAB 250MG · ATC J01FA01 ERYTHROMYCIN · form Tablet · route Oral · ingredients ERYTHROMYCIN 250 MG · company Abbott laboratories, limited · schedule Prescription
Check this DIN again · Health Canada product record

Erythromid: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1796 · Verify on the e-Formulary ↗ (DIN 00244635)

Source record
DIN 00244635: Erythromid Raw flags: notABenefit=Y, sec3=Y Item: 081212001; group id 22; item number 0037; lccId None; manufacturer id ABB Source form: Tab; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00244635 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1796
Interchangeable products
Erythro-Base · DIN 00682020 · $0.1865
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00244635
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2008-06-06 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:12 Erythromycins) and how they are covered

Matched class: 08:12:12 Erythromycins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AZITHROMYCIN, CLARITHROMYCIN, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE 08:12:12 Erythromycins

AZITHROMYCIN

· 28 products · Listed, not a benefit (6), General benefit (21), Limited Use, codes 549 (1) · strengths: 100mg/5mL, 200mg/5mL, 250mg, 600mg · O/L-15mL Pk, O/L-22.5mL Pk, O/L-37.5mL Pk, Tab

CLARITHROMYCIN

· 25 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 500mg, 125mg/5mL, 250mg/5mL, 250mg · ER Tab, Ped Gran, Susp, Tab

ERYTHROMYCIN ESTOLATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg/mL · O/L

ERYTHROMYCIN ETHYLSUCCINATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg/mL, 80mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:12
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

Erythro-Base · DIN 00682020 Shortage status: discontinued (2022-04-01, reported by AA PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00682020

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Erythromid: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026